SHERIDAN, WYOMING - May 10, 2026 - Fette Compacting has formally introduced its comprehensive R&D Solutions program, transitioning the company from a traditional equipment supplier to an integrated process partner for pharmaceutical manufacturers. The newly structured service framework supports drug developers from initial powder formulation through to validated commercial serial production. By embedding Quality by Design principles early in the development lifecycle, the initiative directly addresses the critical need to accelerate time-to-market and maximize effective patent exclusivity periods. This strategic realignment aims to eliminate isolated development steps, ensuring that complex critical material attributes are seamlessly aligned with final production parameters.
Implementing Quality by Design Workflows
Modern tablet development relies heavily on structured Quality by Design methodologies rather than trial-and-error adjustments. The process systematically connects critical material attributes, controllable machine parameters, and the required quality attributes of the final product. Technical specialists at the company emphasize that establishing robust manufacturing processes requires a deep understanding of how specific products interact with compression machinery. The primary objective is to define secure design spaces where production runs reliably and tablet quality remains consistently within regulatory specifications.
Advanced Powder Characterization and Analysis
The initial development phase focuses heavily on identifying complex powder properties that dictate compaction viability. Engineers utilize analytical methods such as laser diffraction spectroscopy alongside the dedicated F Lab 10 compaction analysis system to determine flow behavior, moisture content, and optimal pressing forces. This physical testing can be executed using extremely small powder quantities, providing a significant material advantage during the early stages of experimental drug formulation. The resulting data generates a highly detailed material profile that serves as the foundational baseline for all subsequent manufacturing decisions.
AI-Driven Formulation Database
Translating raw material data into a viable commercial formulation traditionally requires extensive and time-consuming laboratory testing. To bypass these manual trials, the company utilizes its Qualified Expert Database, which processes new analytical results through artificial intelligence algorithms. The software cross-references incoming powder data against historical tableting metrics compiled over more than seven decades of industrial operations. Instead of relying on incremental physical adjustments, the system provides production teams with immediate, data-backed recommendations for ideal machine configurations and component selection.
Emulator Technologies for Predictable Scale-Up
Transitioning from laboratory environments to commercial production volumes frequently introduces costly mechanical and formulation imbalances. Variations in batch sizes, throughput rates, and machine dynamics can rapidly disrupt previously stabilized compression processes. Fette Compacting deploys specialized emulator technologies to optimize individual process steps digitally before initiating physical production runs on the factory floor. Additionally, the company conducts and thoroughly documents feasibility studies to assess formulation changes, allowing pharmaceutical operators to identify potential scale-up risks early in the development timeline.
Real-Time Process Analytical Technology
Maintaining continuous quality control during active production is critical to preventing large-scale batch rejections. The integration of embedded Process Analytical Technology utilizes near-infrared spectroscopy to measure critical product traits, such as active pharmaceutical ingredient content, entirely in real time. This non-destructive scanning method ensures that tablets are continuously monitored without interrupting the physical production line. If the integrated system detects compositional deviations, defective units are immediately rejected, enabling operators to apply on-the-fly mechanical corrections before significant material loss occurs.
GMP Services and Strategic Partnerships
Achieving market readiness requires strict adherence to regulatory standards well beyond the initial mechanical setup. To manage this phase, the R&D Solutions framework includes comprehensive GMP services executed in collaboration with CMIC, a contracted partner based in the United States. This partnership facilitates the formal transfer of processes to production scale, encompassing the statistical evaluation of validation runs and the compliant manufacturing of clinical batches. By shifting toward a strategic process partnership, manufacturers benefit from a continuous development methodology marked by fewer operational interfaces and accelerated project timelines.
To summarize the operational advantages of the integrated platform, the structured offering delivers:
- Shorter development cycles utilizing data-driven equipment recommendations instead of manual trials
- Minimized material waste through immediate, real-time quality deviation detection
- Highly predictable scale-up phases supported by advanced emulation platforms
- Accelerated commercial market entry driven by optimized, end-to-end lifecycle processes